Renaissance Technologies’s Acura Pharmaceuticals ACUR Stock Holding History

Renaissance Technologies’s Portfolio ACUR Stock Details ACUR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-113,220	Closed	-$87K	–	3589
2016 Q4	$87K	Buy	113,220 +31,300	+38%	+$32.7K	﹤0.01%	3118
2016 Q3	$131K	Buy	81,920 +6,300	+8%	+$11.2K	﹤0.01%	3141
2016 Q2	$140K	Buy	75,620 +17,500	+30%	+$45.2K	﹤0.01%	3115
2016 Q1	$164K	Buy	58,120 +5,300	+10%	+$11.3K	﹤0.01%	3138
2015 Q4	$132K	Buy	52,820 +4,000	+8%	+$9.72K	﹤0.01%	3076
2015 Q3	$115K	Buy	48,820 +13,280	+37%	+$45.2K	﹤0.01%	2994
2015 Q2	$175K	Buy	35,540 +9,760	+38%	+$40.5K	﹤0.01%	3009
2015 Q1	$102K	Buy	25,780 +7,480	+41%	+$23.9K	﹤0.01%	3012
2014 Q4	$41K	Buy	18,300 +9,320	+104%	+$25.8K	﹤0.01%	2889
2014 Q3	$35K	Buy	8,980 +6,440	+254%	+$30.2K	﹤0.01%	2726
2014 Q2	$14K	Buy	+2,540	New	+$15.4K	﹤0.01%	2748

Other funds holding ACUR

EWM

Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return

Renaissance Technologies's ACUR Position: Q1 2017 in Review

Renaissance Technologies sold out of Acura Pharmaceuticals (ACUR) in Q1 2017, closing a stake of 113,220 shares — an estimated $87K sold.

Renaissance Technologies first reported a position in ACUR in Q2 2014 and held it in 11 quarters. The position peaked at $175K in Q2 2015. 3 funds tracked by Wall St. Rank hold ACUR as of Q1 2017.

Renaissance Technologies reported no remaining Acura Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
Renaissance Technologies sold 113,220 Acura Pharmaceuticals shares in Q1 2017, an estimated $87K.
Renaissance Technologies first reported a position in Acura Pharmaceuticals in Q2 2014 and held it in 11 quarters.
Renaissance Technologies's Acura Pharmaceuticals position peaked at $175K in Q2 2015.
3 funds tracked by Wall St. Rank held Acura Pharmaceuticals as of Q1 2017.

Based on Renaissance Technologies's 13F filing for Q1 2017, filed 12 May 2017.